FERROUS SULFATE REDUCES CIMETIDINE ABSORPTION

被引:3
作者
CAMPBELL, NRC [1 ]
HASINOFF, BB [1 ]
MEDDINGS, JB [1 ]
ANDERSON, WD [1 ]
ROBERTSON, S [1 ]
GRANBERG, K [1 ]
机构
[1] UNIV MANITOBA,FAC PHARM,WINNIPEG R3T 2N2,MANITOBA,CANADA
关键词
DRUG INTERACTION; DRUG ABSORPTION; IRON; HISTAMINE-2; BLOCKERS; COMPLEX FORMATION; PEPTIC ULCER DISEASE;
D O I
10.1007/BF01295926
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
A variety of drugs that bind to iron have significant reductions in absorption when coadministered with iron compounds. Cimetidine has a structure that would suggest strong binding to iron ions. In vitro experiments were performed to examine a variety of characteristics of the binding of iron to cimetidine. Further studies were conducted to determine the effect of concurrent administration of ferrous sulfate on cimetidine absorption in an in vivo isolated perfused rat jejunal model of drug absorption. The dose of cimetidine was chosen to represent a human dose of 300 mg, while the ferrous sulfate doses were chosen to represent 150- and 300-mg doses. The higher ferrous sulfate dose completely inhibited cimetidine absorption (P < 0.01), while the lower dose of ferrous sulfate caused a 63% reduction in cimetidine absorption (P < 0.05). In vitro iron in its ferrous form rapidly oxidizes to the ferric form. The ferric form of iron binds to cimetidine and may be the cause of the decreased cimetidine absorption. Care should be taken in prescribing iron supplements with cimetidine.
引用
收藏
页码:950 / 954
页数:5
相关论文
共 18 条
[1]  
BRUNTON LL, 1990, PHARMACOL BASIS THER, P894
[2]   ALTERATION OF METHYLDOPA ABSORPTION, METABOLISM, AND BLOOD-PRESSURE CONTROL CAUSED BY FERROUS SULFATE AND FERROUS GLUCONATE [J].
CAMPBELL, N ;
PADDOCK, V ;
SUNDARAM, R .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1988, 43 (04) :381-386
[3]  
CAMPBELL NRC, 1990, CLIN INVEST MED, V13, P329
[4]   FERROUS SULFATE REDUCES LEVODOPA BIOAVAILABILITY - CHELATION AS A POSSIBLE MECHANISM [J].
CAMPBELL, NRC ;
HASINOFF, B .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1989, 45 (03) :220-225
[5]   SINEMET-FERROUS SULFATE INTERACTION IN PATIENTS WITH PARKINSONS-DISEASE [J].
CAMPBELL, NRC ;
RANKINE, D ;
GOODRIDGE, AE ;
HASINOFF, BB ;
KARA, M .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 30 (04) :599-605
[6]   NORFLOXACIN INTERACTION WITH ANTACIDS AND MINERALS [J].
CAMPBELL, NRC ;
KARA, M ;
HASINOFF, BB ;
HADDARA, WM ;
MCKAY, DW .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1992, 33 (01) :115-116
[7]   IRON SUPPLEMENTS - A COMMON CAUSE OF DRUG-INTERACTIONS [J].
CAMPBELL, NRC ;
HASINOFF, BB .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 31 (03) :251-255
[8]   THE EFFECT OF FERROUS SULFATE AND PH ON L-DOPA ABSORPTION [J].
CAMPBELL, RRA ;
HASINOFF, B ;
CHERNENKO, G ;
BARROWMAN, J ;
CAMPBELL, NRC .
CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 1990, 68 (05) :603-607
[9]   INHIBITION OF IRON-ABSORPTION BY OMEPRAZOLE IN RAT MODEL [J].
GOLUBOV, J ;
FLANAGAN, P ;
ADAMS, P .
DIGESTIVE DISEASES AND SCIENCES, 1991, 36 (04) :405-408
[10]  
HILLMAN RS, 1990, PHARMACOL BASIS THER, P1277